Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel Free SBTX Stock Alerts

SkinBioTherapeutics (SBTX) Competitors

SkinBioTherapeutics logo
GBX 6.30 +0.55 (+9.57%)
As of 08:05 AM Eastern
Compare

SBTX vs. MPH, 4BB, FARN, POLB, and REDX

Should you buy SkinBioTherapeutics stock or one of its competitors? SkinBioTherapeutics's main competitors and comparable companies include Mereo BioPharma Group plc (MPH.L) (MPH), 4basebio (4BB), Faron Pharmaceuticals Oy (FARN), Poolbeg Pharma (POLB), and Redx Pharma (REDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does SkinBioTherapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Mereo BioPharma Group plc (MPH.L) (LON:MPH) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

In the previous week, SkinBioTherapeutics had 1 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 1 mentions for SkinBioTherapeutics and 0 mentions for Mereo BioPharma Group plc (MPH.L). Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Mereo BioPharma Group plc (MPH.L) Neutral
SkinBioTherapeutics Neutral

3.5% of SkinBioTherapeutics shares are owned by institutional investors. 2.7% of SkinBioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mereo BioPharma Group plc (MPH.L)N/A N/A N/A
SkinBioTherapeutics -8.73%-5.25%-61.18%

Mereo BioPharma Group plc (MPH.L) has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A
SkinBioTherapeutics£5.23M3.12-£3.71M-£0.16N/A

Summary

SkinBioTherapeutics beats Mereo BioPharma Group plc (MPH.L) on 5 of the 9 factors compared between the two stocks.

How does SkinBioTherapeutics compare to 4basebio?

4basebio (LON:4BB) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, SkinBioTherapeutics had 1 more articles in the media than 4basebio. MarketBeat recorded 1 mentions for SkinBioTherapeutics and 0 mentions for 4basebio. 4basebio's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
4basebio Neutral
SkinBioTherapeutics Neutral

0.9% of 4basebio shares are owned by institutional investors. Comparatively, 3.5% of SkinBioTherapeutics shares are owned by institutional investors. 12.1% of 4basebio shares are owned by company insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

4basebio currently has a consensus price target of GBX 1,400, suggesting a potential upside of 150.90%. Given 4basebio's stronger consensus rating and higher probable upside, equities research analysts clearly believe 4basebio is more favorable than SkinBioTherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4basebio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
SkinBioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

4basebio has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat 4basebio's return on equity.

Company Net Margins Return on Equity Return on Assets
4basebioN/A -231.29% -54.30%
SkinBioTherapeutics -8.73%-5.25%-61.18%

4basebio has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.104, indicating that its stock price is 90% less volatile than the broader market.

SkinBioTherapeutics has higher revenue and earnings than 4basebio. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than 4basebio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4basebio£1.69M51.04-£9.84M-£109.00N/A
SkinBioTherapeutics£5.23M3.12-£3.71M-£0.16N/A

Summary

4basebio beats SkinBioTherapeutics on 9 of the 15 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy (LON:FARN) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat SkinBioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Faron Pharmaceuticals OyN/A 476.49% -70.00%
SkinBioTherapeutics -8.73%-5.25%-61.18%

Faron Pharmaceuticals Oy has a beta of 1.116, indicating that its share price is 12% more volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.104, indicating that its share price is 90% less volatile than the broader market.

3.8% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 3.5% of SkinBioTherapeutics shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by company insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, SkinBioTherapeutics had 1 more articles in the media than Faron Pharmaceuticals Oy. MarketBeat recorded 1 mentions for SkinBioTherapeutics and 0 mentions for Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Faron Pharmaceuticals Oy Neutral
SkinBioTherapeutics Neutral

SkinBioTherapeutics has higher revenue and earnings than Faron Pharmaceuticals Oy. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Faron Pharmaceuticals OyN/AN/A-£60.23M-£11.52N/A
SkinBioTherapeutics£5.23M3.12-£3.71M-£0.16N/A

Summary

Faron Pharmaceuticals Oy beats SkinBioTherapeutics on 6 of the 11 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Poolbeg Pharma had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 2 mentions for Poolbeg Pharma and 1 mentions for SkinBioTherapeutics. Poolbeg Pharma's average media sentiment score of 0.59 beat SkinBioTherapeutics' score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Poolbeg Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
SkinBioTherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Poolbeg Pharma has a beta of 1.828, indicating that its share price is 83% more volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.104, indicating that its share price is 90% less volatile than the broader market.

SkinBioTherapeutics has higher revenue and earnings than Poolbeg Pharma. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A
SkinBioTherapeutics£5.23M3.12-£3.71M-£0.16N/A

5.1% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 3.5% of SkinBioTherapeutics shares are owned by institutional investors. 7.5% of Poolbeg Pharma shares are owned by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Poolbeg Pharma has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat Poolbeg Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Poolbeg PharmaN/A -55.47% -21.33%
SkinBioTherapeutics -8.73%-5.25%-61.18%

Summary

Poolbeg Pharma beats SkinBioTherapeutics on 8 of the 12 factors compared between the two stocks.

How does SkinBioTherapeutics compare to Redx Pharma?

Redx Pharma (LON:REDX) and SkinBioTherapeutics (LON:SBTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

72.7% of Redx Pharma shares are held by institutional investors. Comparatively, 3.5% of SkinBioTherapeutics shares are held by institutional investors. 18.4% of Redx Pharma shares are held by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Redx Pharma has a beta of -0.53, indicating that its share price is 153% less volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.104, indicating that its share price is 90% less volatile than the broader market.

SkinBioTherapeutics has higher revenue and earnings than Redx Pharma. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A
SkinBioTherapeutics£5.23M3.12-£3.71M-£0.16N/A

Redx Pharma has a net margin of 0.00% compared to SkinBioTherapeutics' net margin of -8.73%. SkinBioTherapeutics' return on equity of -5.25% beat Redx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Redx PharmaN/A -180.80% -43.95%
SkinBioTherapeutics -8.73%-5.25%-61.18%

In the previous week, SkinBioTherapeutics had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for SkinBioTherapeutics and 0 mentions for Redx Pharma. Redx Pharma's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.

Company Overall Sentiment
Redx Pharma Neutral
SkinBioTherapeutics Neutral

Summary

SkinBioTherapeutics beats Redx Pharma on 6 of the 11 factors compared between the two stocks.

Get SkinBioTherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

Export
MetricSkinBioTherapeuticsBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£16.33M£3.98B£7.31B£2.89B
Dividend YieldN/A3.63%2.52%6.22%
P/E Ratio-39.3813.88274.10366.58
Price / Sales3.121,437.48672.6190,068.21
Price / Cash9.00113.2977.8027.89
Price / Book3.7515.4510.486.42
Net Income-£3.71M-£22.82M£3.49B£5.89B
7 Day Performance-29.09%-1.68%-0.68%0.20%
1 Month Performance-32.33%-6.15%-3.18%6.38%
1 Year Performance-61.11%30.67%15.13%19.26%

SkinBioTherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
SkinBioTherapeutics
N/AGBX 6.30
+9.6%		N/A-66.0%£16.33M£5.23MN/A11
MPH
Mereo BioPharma Group plc (MPH.L)
N/AN/AN/AN/A£89.76MN/AN/A50
4BB
4basebio
N/AGBX 496.80
+3.5%		GBX 1,400
+181.8%		-24.6%£76.93M£1.69MN/A101
FARN
Faron Pharmaceuticals Oy
N/AGBX 35.39
+1.1%		N/A-81.6%£71.80MN/AN/A34
POLB
Poolbeg Pharma
N/AGBX 8.40
0.0%		N/A+134.8%£64.11MN/AN/A12

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:SBTX) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Congress Passes Landmark Digital Asset Law Wall Street Is Watching
The House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...
Awesomely | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel